A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

In a trial of patients with high grade serous ovarian cancer (HGSOC), addition of the ATR inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to gemcitabine alone but biomarkers predictive of treatment are lacking. Here we report a candidate biomarker of response t...

Descripción completa

Detalles Bibliográficos
Autores principales: Konstantinopoulos, Panagiotis A., da Costa, Alexandre André B. A., Gulhan, Doga, Lee, Elizabeth K., Cheng, Su-Chun, Hendrickson, Andrea E. Wahner, Kochupurakkal, Bose, Kolin, David L., Kohn, Elise C., Liu, Joyce F., Stover, Elizabeth H., Curtis, Jennifer, Tayob, Nabihah, Polak, Madeline, Chowdhury, Dipanjan, Matulonis, Ursula A., Färkkilä, Anniina, D’Andrea, Alan D., Shapiro, Geoffrey I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458434/
https://www.ncbi.nlm.nih.gov/pubmed/34552099
http://dx.doi.org/10.1038/s41467-021-25904-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458434/
https://www.ncbi.nlm.nih.gov/pubmed/34552099
http://dx.doi.org/10.1038/s41467-021-25904-w

Ejemplares similares